Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Hong Kong · Delayed Price · Currency is HKD 22.18
+0.20 (0.91%)
May 7, 2026, 4:08 PM HKT
HKG:6826 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,399 | 2,446 | 2,680 | 2,635 | 2,103 | 1,750 | |
Revenue Growth (YoY) | -9.54% | -8.71% | 1.70% | 25.27% | 20.19% | 32.14% |
Cost of Revenue | 760.73 | 756.79 | 843.12 | 788.14 | 656.52 | 490.37 |
Gross Profit | 1,638 | 1,690 | 1,837 | 1,847 | 1,447 | 1,260 |
Selling, General & Admin | 1,213 | 1,248 | 1,228 | 1,237 | 1,085 | 898.43 |
Research & Development | 201.35 | 197.78 | 238.93 | 220.1 | 182.19 | 167.6 |
Other Operating Expenses | 8.95 | 4.62 | -2.23 | -1.97 | 15.52 | -3.18 |
Operating Expenses | 1,424 | 1,450 | 1,465 | 1,455 | 1,283 | 1,063 |
Operating Income | 214.27 | 239.23 | 372.03 | 391.79 | 164.38 | 196.9 |
Interest Expense | -18.65 | -18.88 | -18.06 | -7.3 | -7.6 | -4.96 |
Interest & Investment Income | 74.51 | 76.91 | 73.98 | 78.15 | 88.56 | 155.75 |
Earnings From Equity Investments | 0.01 | 0.01 | 0.99 | 0.46 | 3.51 | 2.19 |
Other Non Operating Income (Expenses) | 108.28 | 110.18 | 11.3 | 44.53 | -13.3 | 32.77 |
EBT Excluding Unusual Items | 378.41 | 407.44 | 440.23 | 507.63 | 235.54 | 382.65 |
Impairment of Goodwill | -151.09 | -151.09 | - | - | - | - |
Gain (Loss) on Sale of Investments | 31.14 | 31.06 | 25.92 | - | - | - |
Gain (Loss) on Sale of Assets | -0.34 | - | - | 0.63 | 0.19 | - |
Asset Writedown | -20.7 | -25.07 | - | - | - | - |
Legal Settlements | -27.6 | -27.6 | - | - | - | - |
Other Unusual Items | 22.37 | 4.5 | - | - | - | - |
Pretax Income | 232.18 | 239.25 | 466.15 | 508.26 | 235.73 | 382.65 |
Income Tax Expense | 36.01 | 30.92 | 89.9 | 95.99 | 45.4 | 35.37 |
Earnings From Continuing Operations | 196.17 | 208.32 | 376.24 | 412.27 | 190.33 | 347.28 |
Minority Interest in Earnings | 38.09 | 42.69 | 44.2 | 3.85 | -9.86 | 4.95 |
Net Income | 234.26 | 251.01 | 420.45 | 416.12 | 180.47 | 352.23 |
Net Income to Common | 234.26 | 251.01 | 420.45 | 416.12 | 180.47 | 352.23 |
Net Income Growth | -43.31% | -40.30% | 1.04% | 130.58% | -48.76% | 53.10% |
Shares Outstanding (Basic) | 231 | 232 | 233 | 237 | 340 | 345 |
Shares Outstanding (Diluted) | 231 | 232 | 233 | 237 | 340 | 345 |
Shares Change (YoY) | -0.67% | -0.56% | -1.77% | -30.24% | -1.46% | -0.62% |
EPS (Basic) | 1.01 | 1.08 | 1.80 | 1.75 | 0.53 | 1.02 |
EPS (Diluted) | 1.01 | 1.08 | 1.80 | 1.75 | 0.53 | 1.02 |
EPS Growth | -42.93% | -39.96% | 2.86% | 230.53% | -48.01% | 54.06% |
Free Cash Flow | 183.37 | 306.78 | 286.39 | 368.85 | -77.91 | 71.41 |
Free Cash Flow Per Share | 0.79 | 1.32 | 1.23 | 1.55 | -0.23 | 0.21 |
Dividend Per Share | 1.000 | 1.000 | 1.000 | 0.510 | 0.286 | 0.500 |
Dividend Growth | - | - | 96.00% | 78.58% | -42.86% | 40.02% |
Gross Margin | 68.29% | 69.06% | 68.54% | 70.09% | 68.79% | 71.98% |
Operating Margin | 8.93% | 9.78% | 13.88% | 14.87% | 7.81% | 11.25% |
Profit Margin | 9.76% | 10.26% | 15.69% | 15.79% | 8.58% | 20.13% |
Free Cash Flow Margin | 7.64% | 12.54% | 10.69% | 14.00% | -3.70% | 4.08% |
EBITDA | 393.67 | 418.16 | 549.05 | 565.26 | 343 | 332.03 |
EBITDA Margin | 16.41% | 17.09% | 20.49% | 21.45% | 16.31% | 18.97% |
D&A For EBITDA | 179.41 | 178.93 | 177.03 | 173.47 | 178.62 | 135.13 |
EBIT | 214.27 | 239.23 | 372.03 | 391.79 | 164.38 | 196.9 |
EBIT Margin | 8.93% | 9.78% | 13.88% | 14.87% | 7.81% | 11.25% |
Effective Tax Rate | 15.51% | 12.93% | 19.29% | 18.89% | 19.26% | 9.24% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.